Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
ROPINIROLE (AS HYDROCHLORIDE)
Clonmel Healthcare Ltd
ROPINIROLE (AS HYDROCHLORIDE)
8 Milligram
Tablet Prolonged Release
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE USER ROPIRADE XL 2MG PROLONGED-RELEASE TABLETS ROPIRADE XL 4MG PROLONGED-RELEASE TABLETS ROPIRADE XL 8MG PROLONGED-RELEASE TABLETS Ropinirole READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any more questions, ask your doctor or pharmacist. - This medicine has been prescribed for you personally. Don’t pass it on to other people. It may harm them even if their symptoms seem to be the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Ropirade XL is and what it is used for 2. Before you take Ropirade XL 3. How to take Ropirade XL 5. Possible side effects 6. How to store Ropirade XL 7. Further information 1. WHAT ROPIRADE XL IS AND WHAT IT IS USED FOR Ropirade XL prolonged-release tablets are used to treat Parkinson’s disease. The active ingredient in Ropirade is ropinirole, which belongs to a group of medicines called dopamine agonists. Dopamine agonists affect the brain in a similar way to a natural substance called dopamine. People with Parkinson’s disease have low levels of dopamine in some parts of their brains. Ropinirole has effects similar to those of natural dopamine, so it helps to reduce the symptoms of Parkinson’s disease. 2. BEFORE YOU TAKE ROPIRADE XL DO NOT TAKE ROPIRADE XL if you are allergic (hypersensitive) to ropinirole or any of the other ingredients of Ropirade XL; (see section 6) if you have serious kidney disease if you have liver disease. Tell your doctor if you think any of these Baca dokumen lengkapnya
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ropirade XL 8 mg prolonged-release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 8 mg of ropinirole (as hydrochloride). For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release tablet. 8 mg prolonged-release tablets: red, oval biconvex tablets 19.2x 10.2 ± 0.2 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of Parkinson's disease under the following conditions: Initial treatment as monotherapy, in order to delay the introduction of levodopa In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use Adults Individual dose titration against efficacy and tolerability is recommended. Ropirade XL prolonged-release tablets should be taken once a day, at a similar time each day. The prolonged-release tablets may be taken with or without food (see section 5.2). Ropirade XL 2 mg prolonged-release tablets must be swallowed whole and must not be chewed, crushed or divided. _Initial titration_ The starting dose of ropinirole prolonged-release tablets is 2 mg once daily for the first week; this should be increased to 4 mg once daily from the second week of treatment. A therapeutic response may be seen at a dose of 4 mg once daily of ropinirole prolonged-release tablets. Patients who initiate treatment with a dose of 2 mg/day of ropinirole prolonged-release tablets and who experience side effects that they cannot tolerate, may benefit from switching to treatment with ropinirole film-coated (immediate release) tablets at a lower Baca dokumen lengkapnya